Notice Information
Notice Title
National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England
Notice Description
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Lot Information
Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Atezolizumab - Lot 1NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Bevacizumab (Avastin) - Lot 2NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Bevacizumab (Zirabev) - Lot 3NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Bevacizumab (Aybintio) - Lot 4NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Bleomycin - Lot 5NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Cyclophosphamide Bags - Lot 11NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Obinutuzumab - Lot 33NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Pemetrexed - Lot 38NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Fludarabine Bags - Lot 17NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Ganciclovir - Lot 27NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Methotrexate - Lot 31NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fluorouracil Bags - Lot 19NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Bortezomib - Lot 6NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Pertuzumab - Lot 39NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Carboplatin - Lot 7NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Panitumumab - Lot 36NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Vinorelbine - Lot 50NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Irinotecan - Lot 30NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fludarabine Syringes - Lot 16NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Trastuzumab (Trasimera) - Lot 47NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Pembrolizumab - Lot 37NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Cetuximab - Lot 8NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Docetaxel - Lot 13NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fluorouracil Syringes - Lot 18NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Doxorubicin - Lot 14NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Cytarabine - Lot 12NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Nivolumab - Lot 32NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Cyclophosphamide Syringes - Lot 10NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Trastuzumab (Herzuma) - Lot 44NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Oxaliplatin - Lot 34NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Vinblastine - Lot 48NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Cisplatin - Lot 9NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Gemcitabine - Lot 28NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Vincristine - Lot 49NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Trastuzumab (Herceptin) - Lot 43NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Trastuzumab (Ontruzant) - Lot 46NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Epirubicin - Lot 15NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Rituximab (Truxima) - Lot 42NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Rituximab (Mabthera) - Lot 40NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Rituximab (Rixathon) - Lot 41NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Paclitaxel - Lot 35NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Trastuzumab (Kanjinti) - Lot 45NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-02ab4a
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/009177-2021
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 28 Apr 20214 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 18 Mar 20214 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Contact Name
- Philip Grieve
- Contact Email
- philip.grieve@nhs.net
- Contact Phone
- Not specified
Buyer Location
- Locality
- RUNCORN
- Postcode
- WA7 2ES
- Post Town
- Warrington
- Country
- England
-
- Major Region (ITL 1)
- TLD North West (England)
- Basic Region (ITL 2)
- TLD7 Merseyside
- Small Region (ITL 3)
- TLD71 East Merseyside
- Delivery Location
- Not specified
-
- Local Authority
- Halton
- Electoral Ward
- Halton Lea
- Westminster Constituency
- Runcorn and Helsby
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-02ab4a-2021-04-28T16:29:04+01:00",
"date": "2021-04-28T16:29:04+01:00",
"ocid": "ocds-h6vhtk-02ab4a",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-02ab4a",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
"mainProcurementCategory": "goods",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"lots": [
{
"id": "25",
"title": "Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "22",
"title": "Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "1",
"title": "Atezolizumab - Lot 1",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "2",
"title": "Bevacizumab (Avastin) - Lot 2",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "3",
"title": "Bevacizumab (Zirabev) - Lot 3",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "4",
"title": "Bevacizumab (Aybintio) - Lot 4",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "5",
"title": "Bleomycin - Lot 5",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "11",
"title": "Cyclophosphamide Bags - Lot 11",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "33",
"title": "Obinutuzumab - Lot 33",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "38",
"title": "Pemetrexed - Lot 38",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "17",
"title": "Fludarabine Bags - Lot 17",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "27",
"title": "Ganciclovir - Lot 27",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "31",
"title": "Methotrexate - Lot 31",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "23",
"title": "Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "19",
"title": "Fluorouracil Bags - Lot 19",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "6",
"title": "Bortezomib - Lot 6",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "39",
"title": "Pertuzumab - Lot 39",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "7",
"title": "Carboplatin - Lot 7",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "36",
"title": "Panitumumab - Lot 36",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "50",
"title": "Vinorelbine - Lot 50",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "21",
"title": "Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "30",
"title": "Irinotecan - Lot 30",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "16",
"title": "Fludarabine Syringes - Lot 16",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "47",
"title": "Trastuzumab (Trasimera) - Lot 47",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "24",
"title": "Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "37",
"title": "Pembrolizumab - Lot 37",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "8",
"title": "Cetuximab - Lot 8",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "13",
"title": "Docetaxel - Lot 13",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "18",
"title": "Fluorouracil Syringes - Lot 18",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "14",
"title": "Doxorubicin - Lot 14",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "26",
"title": "Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "12",
"title": "Cytarabine - Lot 12",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "32",
"title": "Nivolumab - Lot 32",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "10",
"title": "Cyclophosphamide Syringes - Lot 10",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "44",
"title": "Trastuzumab (Herzuma) - Lot 44",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "34",
"title": "Oxaliplatin - Lot 34",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "48",
"title": "Vinblastine - Lot 48",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "9",
"title": "Cisplatin - Lot 9",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "28",
"title": "Gemcitabine - Lot 28",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "49",
"title": "Vincristine - Lot 49",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "43",
"title": "Trastuzumab (Herceptin) - Lot 43",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "46",
"title": "Trastuzumab (Ontruzant) - Lot 46",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "15",
"title": "Epirubicin - Lot 15",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "42",
"title": "Rituximab (Truxima) - Lot 42",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "40",
"title": "Rituximab (Mabthera) - Lot 40",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "41",
"title": "Rituximab (Rixathon) - Lot 41",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "35",
"title": "Paclitaxel - Lot 35",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "45",
"title": "Trastuzumab (Kanjinti) - Lot 45",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
},
{
"id": "20",
"title": "Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20",
"description": "NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.",
"awardCriteria": {
"criteria": [
{
"type": "price"
}
]
},
"hasOptions": false,
"status": "cancelled"
}
],
"items": [
{
"id": "25",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "25"
},
{
"id": "22",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "22"
},
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "1"
},
{
"id": "2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "2"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "3"
},
{
"id": "4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "4"
},
{
"id": "5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "5"
},
{
"id": "11",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "11"
},
{
"id": "33",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "33"
},
{
"id": "38",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "38"
},
{
"id": "17",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "17"
},
{
"id": "27",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "27"
},
{
"id": "31",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "31"
},
{
"id": "23",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "23"
},
{
"id": "19",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "19"
},
{
"id": "6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "6"
},
{
"id": "39",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "39"
},
{
"id": "7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "7"
},
{
"id": "36",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "36"
},
{
"id": "50",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "50"
},
{
"id": "21",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "21"
},
{
"id": "30",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "30"
},
{
"id": "16",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "16"
},
{
"id": "47",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "47"
},
{
"id": "24",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "24"
},
{
"id": "37",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "37"
},
{
"id": "8",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "8"
},
{
"id": "13",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "13"
},
{
"id": "18",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "18"
},
{
"id": "14",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "14"
},
{
"id": "26",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "26"
},
{
"id": "12",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "12"
},
{
"id": "32",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "32"
},
{
"id": "10",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "10"
},
{
"id": "44",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "44"
},
{
"id": "34",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "34"
},
{
"id": "48",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "48"
},
{
"id": "9",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "9"
},
{
"id": "28",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "28"
},
{
"id": "49",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "49"
},
{
"id": "43",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "43"
},
{
"id": "46",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "46"
},
{
"id": "15",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "15"
},
{
"id": "42",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "42"
},
{
"id": "40",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "40"
},
{
"id": "41",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "41"
},
{
"id": "35",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "35"
},
{
"id": "45",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "45"
},
{
"id": "20",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. Framework intended for use by the NHS in England, the Department of Health and Social Care and Public Health England. The framework may also be used by private sector contractors and agents working on behalf of the above."
},
"relatedLot": "20"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"techniques": {
"hasFrameworkAgreement": true
},
"coveredBy": [
"GPA"
]
},
"awards": [
{
"id": "009177-2021-1",
"relatedLots": [
"25"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-2",
"relatedLots": [
"22"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-3",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-4",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-5",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-6",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-7",
"relatedLots": [
"2"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-8",
"relatedLots": [
"2"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-9",
"relatedLots": [
"2"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-10",
"relatedLots": [
"2"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-11",
"relatedLots": [
"3"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-12",
"relatedLots": [
"3"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-13",
"relatedLots": [
"3"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-14",
"relatedLots": [
"4"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-15",
"relatedLots": [
"4"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-16",
"relatedLots": [
"4"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-17",
"relatedLots": [
"5"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-18",
"relatedLots": [
"11"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-19",
"relatedLots": [
"33"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-20",
"relatedLots": [
"38"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-21",
"relatedLots": [
"17"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-22",
"relatedLots": [
"27"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-23",
"relatedLots": [
"31"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-24",
"relatedLots": [
"23"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-25",
"relatedLots": [
"19"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-26",
"relatedLots": [
"6"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-27",
"relatedLots": [
"39"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-28",
"relatedLots": [
"39"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-29",
"relatedLots": [
"7"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-30",
"relatedLots": [
"36"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-31",
"relatedLots": [
"36"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-32",
"relatedLots": [
"50"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-33",
"relatedLots": [
"21"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-34",
"relatedLots": [
"30"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-35",
"relatedLots": [
"16"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-36",
"relatedLots": [
"47"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-37",
"relatedLots": [
"47"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-38",
"relatedLots": [
"47"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-39",
"relatedLots": [
"47"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-40",
"relatedLots": [
"24"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-41",
"relatedLots": [
"37"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-42",
"relatedLots": [
"37"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-43",
"relatedLots": [
"8"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-44",
"relatedLots": [
"8"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-45",
"relatedLots": [
"13"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-46",
"relatedLots": [
"18"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-47",
"relatedLots": [
"18"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-48",
"relatedLots": [
"14"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-49",
"relatedLots": [
"26"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-50",
"relatedLots": [
"12"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-51",
"relatedLots": [
"32"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-52",
"relatedLots": [
"32"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-53",
"relatedLots": [
"32"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-54",
"relatedLots": [
"32"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-55",
"relatedLots": [
"10"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-56",
"relatedLots": [
"10"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-57",
"relatedLots": [
"44"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-58",
"relatedLots": [
"44"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-59",
"relatedLots": [
"44"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-60",
"relatedLots": [
"44"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-61",
"relatedLots": [
"34"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-62",
"relatedLots": [
"48"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-63",
"relatedLots": [
"9"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-64",
"relatedLots": [
"28"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-65",
"relatedLots": [
"49"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-66",
"relatedLots": [
"43"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-67",
"relatedLots": [
"43"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-68",
"relatedLots": [
"43"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-69",
"relatedLots": [
"43"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-70",
"relatedLots": [
"46"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-71",
"relatedLots": [
"46"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-72",
"relatedLots": [
"46"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-73",
"relatedLots": [
"46"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-74",
"relatedLots": [
"15"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-75",
"relatedLots": [
"15"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-76",
"relatedLots": [
"42"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-77",
"relatedLots": [
"42"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-78",
"relatedLots": [
"42"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-79",
"relatedLots": [
"42"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-80",
"relatedLots": [
"40"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-81",
"relatedLots": [
"40"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-82",
"relatedLots": [
"40"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-83",
"relatedLots": [
"40"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-84",
"relatedLots": [
"41"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-85",
"relatedLots": [
"41"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-86",
"relatedLots": [
"41"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-87",
"relatedLots": [
"41"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-88",
"relatedLots": [
"35"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-89",
"relatedLots": [
"45"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
},
{
"id": "009177-2021-90",
"relatedLots": [
"45"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU"
}
]
},
{
"id": "009177-2021-91",
"relatedLots": [
"45"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14571",
"name": "ITH Pharma"
}
]
},
{
"id": "009177-2021-92",
"relatedLots": [
"45"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services"
}
]
},
{
"id": "009177-2021-93",
"relatedLots": [
"20"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd"
}
]
}
],
"parties": [
{
"id": "GB-FTS-2505",
"name": "The NHS Commissioning Board (operating under the name of NHS England)",
"identifier": {
"legalName": "The NHS Commissioning Board (operating under the name of NHS England)"
},
"address": {
"streetAddress": "2nd Floor, Rutland House",
"locality": "Runcorn",
"region": "UK",
"postalCode": "WA7 2ES",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Philip Grieve",
"email": "philip.grieve@nhs.net"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"url": "https://www.england.nhs.uk/",
"buyerProfile": "https://www.england.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "MINISTRY",
"description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-14569",
"name": "Qualasept Ltd t/a Bath ASU",
"identifier": {
"legalName": "Qualasept Ltd t/a Bath ASU"
},
"address": {
"streetAddress": "3 Corsham Science Park, Park Lane, Corsham, Wiltshire",
"locality": "Corsham",
"region": "UK",
"postalCode": "SN13 9FU",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-14570",
"name": "Baxter Healthcare Ltd",
"identifier": {
"legalName": "Baxter Healthcare Ltd"
},
"address": {
"streetAddress": "Wallingford Road, Compton, Newbury, Berkshire, RG20 7QW",
"locality": "Newbury",
"region": "UK",
"postalCode": "RG20 7QW",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-14571",
"name": "ITH Pharma",
"identifier": {
"legalName": "ITH Pharma"
},
"address": {
"streetAddress": "Unit 4, Premier Park, London",
"locality": "London",
"region": "UK",
"postalCode": "NW10 7NZ",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
},
{
"id": "GB-FTS-14572",
"name": "Quantum Aseptic Services",
"identifier": {
"legalName": "Quantum Aseptic Services"
},
"address": {
"streetAddress": "Quantum House, Hobson Industrial Estate, Burnopfield, Co.Durham",
"locality": "Burnopfield",
"region": "UK",
"postalCode": "NE16 6EA",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-497",
"name": "The High Court",
"identifier": {
"legalName": "The High Court"
},
"address": {
"streetAddress": "Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"contactPoint": {
"email": "generaloffice@administrativecourtoffice.justice.gov.uk"
},
"roles": [
"reviewBody"
],
"details": {
"url": "https://www.gov.uk/courts-tribunals"
}
}
],
"buyer": {
"id": "GB-FTS-2505",
"name": "The NHS Commissioning Board (operating under the name of NHS England)"
},
"contracts": [
{
"id": "009177-2021-1",
"awardID": "009177-2021-1",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-2",
"awardID": "009177-2021-2",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-3",
"awardID": "009177-2021-3",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-4",
"awardID": "009177-2021-4",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-5",
"awardID": "009177-2021-5",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-6",
"awardID": "009177-2021-6",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-7",
"awardID": "009177-2021-7",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-8",
"awardID": "009177-2021-8",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-9",
"awardID": "009177-2021-9",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-10",
"awardID": "009177-2021-10",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-11",
"awardID": "009177-2021-11",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-12",
"awardID": "009177-2021-12",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-13",
"awardID": "009177-2021-13",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-14",
"awardID": "009177-2021-14",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-15",
"awardID": "009177-2021-15",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-16",
"awardID": "009177-2021-16",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-17",
"awardID": "009177-2021-17",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-18",
"awardID": "009177-2021-18",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-19",
"awardID": "009177-2021-19",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-20",
"awardID": "009177-2021-20",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-21",
"awardID": "009177-2021-21",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-22",
"awardID": "009177-2021-22",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-23",
"awardID": "009177-2021-23",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-24",
"awardID": "009177-2021-24",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-25",
"awardID": "009177-2021-25",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-26",
"awardID": "009177-2021-26",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-27",
"awardID": "009177-2021-27",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-28",
"awardID": "009177-2021-28",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-29",
"awardID": "009177-2021-29",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-30",
"awardID": "009177-2021-30",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-31",
"awardID": "009177-2021-31",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-32",
"awardID": "009177-2021-32",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-33",
"awardID": "009177-2021-33",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-34",
"awardID": "009177-2021-34",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-35",
"awardID": "009177-2021-35",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-36",
"awardID": "009177-2021-36",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-37",
"awardID": "009177-2021-37",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-38",
"awardID": "009177-2021-38",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-39",
"awardID": "009177-2021-39",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-40",
"awardID": "009177-2021-40",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-41",
"awardID": "009177-2021-41",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-42",
"awardID": "009177-2021-42",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-43",
"awardID": "009177-2021-43",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-44",
"awardID": "009177-2021-44",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-45",
"awardID": "009177-2021-45",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-46",
"awardID": "009177-2021-46",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-47",
"awardID": "009177-2021-47",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-48",
"awardID": "009177-2021-48",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-49",
"awardID": "009177-2021-49",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-50",
"awardID": "009177-2021-50",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-51",
"awardID": "009177-2021-51",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-52",
"awardID": "009177-2021-52",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-53",
"awardID": "009177-2021-53",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-54",
"awardID": "009177-2021-54",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-55",
"awardID": "009177-2021-55",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-56",
"awardID": "009177-2021-56",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-57",
"awardID": "009177-2021-57",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-58",
"awardID": "009177-2021-58",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-59",
"awardID": "009177-2021-59",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-60",
"awardID": "009177-2021-60",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-61",
"awardID": "009177-2021-61",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-62",
"awardID": "009177-2021-62",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-63",
"awardID": "009177-2021-63",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-64",
"awardID": "009177-2021-64",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-65",
"awardID": "009177-2021-65",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-66",
"awardID": "009177-2021-66",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-67",
"awardID": "009177-2021-67",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-68",
"awardID": "009177-2021-68",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-69",
"awardID": "009177-2021-69",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-70",
"awardID": "009177-2021-70",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-71",
"awardID": "009177-2021-71",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-72",
"awardID": "009177-2021-72",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-73",
"awardID": "009177-2021-73",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-74",
"awardID": "009177-2021-74",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-75",
"awardID": "009177-2021-75",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-76",
"awardID": "009177-2021-76",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-77",
"awardID": "009177-2021-77",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-78",
"awardID": "009177-2021-78",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-79",
"awardID": "009177-2021-79",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-80",
"awardID": "009177-2021-80",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-81",
"awardID": "009177-2021-81",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-82",
"awardID": "009177-2021-82",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-83",
"awardID": "009177-2021-83",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-84",
"awardID": "009177-2021-84",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-85",
"awardID": "009177-2021-85",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-86",
"awardID": "009177-2021-86",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-87",
"awardID": "009177-2021-87",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-88",
"awardID": "009177-2021-88",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-89",
"awardID": "009177-2021-89",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-90",
"awardID": "009177-2021-90",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-91",
"awardID": "009177-2021-91",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-92",
"awardID": "009177-2021-92",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
},
{
"id": "009177-2021-93",
"awardID": "009177-2021-93",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2021-03-18T00:00:00Z"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"relatedLot": "25",
"value": 1
},
{
"id": "6",
"measure": "bids",
"relatedLot": "22",
"value": 3
},
{
"id": "11",
"measure": "bids",
"relatedLot": "1",
"value": 4
},
{
"id": "16",
"measure": "bids",
"relatedLot": "1",
"value": 4
},
{
"id": "21",
"measure": "bids",
"relatedLot": "1",
"value": 4
},
{
"id": "26",
"measure": "bids",
"relatedLot": "1",
"value": 4
},
{
"id": "31",
"measure": "bids",
"relatedLot": "2",
"value": 4
},
{
"id": "36",
"measure": "bids",
"relatedLot": "2",
"value": 4
},
{
"id": "41",
"measure": "bids",
"relatedLot": "2",
"value": 4
},
{
"id": "46",
"measure": "bids",
"relatedLot": "2",
"value": 4
},
{
"id": "51",
"measure": "bids",
"relatedLot": "3",
"value": 3
},
{
"id": "56",
"measure": "bids",
"relatedLot": "3",
"value": 3
},
{
"id": "61",
"measure": "bids",
"relatedLot": "3",
"value": 3
},
{
"id": "66",
"measure": "bids",
"relatedLot": "4",
"value": 3
},
{
"id": "71",
"measure": "bids",
"relatedLot": "4",
"value": 3
},
{
"id": "76",
"measure": "bids",
"relatedLot": "4",
"value": 3
},
{
"id": "81",
"measure": "bids",
"relatedLot": "5",
"value": 1
},
{
"id": "86",
"measure": "bids",
"relatedLot": "11",
"value": 3
},
{
"id": "91",
"measure": "bids",
"relatedLot": "33",
"value": 2
},
{
"id": "96",
"measure": "bids",
"relatedLot": "38",
"value": 2
},
{
"id": "101",
"measure": "bids",
"relatedLot": "17",
"value": 1
},
{
"id": "106",
"measure": "bids",
"relatedLot": "27",
"value": 4
},
{
"id": "111",
"measure": "bids",
"relatedLot": "31",
"value": 1
},
{
"id": "116",
"measure": "bids",
"relatedLot": "23",
"value": 3
},
{
"id": "121",
"measure": "bids",
"relatedLot": "19",
"value": 3
},
{
"id": "126",
"measure": "bids",
"relatedLot": "6",
"value": 4
},
{
"id": "131",
"measure": "bids",
"relatedLot": "39",
"value": 3
},
{
"id": "136",
"measure": "bids",
"relatedLot": "39",
"value": 3
},
{
"id": "141",
"measure": "bids",
"relatedLot": "7",
"value": 4
},
{
"id": "146",
"measure": "bids",
"relatedLot": "36",
"value": 3
},
{
"id": "151",
"measure": "bids",
"relatedLot": "36",
"value": 3
},
{
"id": "156",
"measure": "bids",
"relatedLot": "50",
"value": 1
},
{
"id": "161",
"measure": "bids",
"relatedLot": "21",
"value": 3
},
{
"id": "166",
"measure": "bids",
"relatedLot": "30",
"value": 4
},
{
"id": "171",
"measure": "bids",
"relatedLot": "16",
"value": 1
},
{
"id": "176",
"measure": "bids",
"relatedLot": "47",
"value": 4
},
{
"id": "181",
"measure": "bids",
"relatedLot": "47",
"value": 4
},
{
"id": "186",
"measure": "bids",
"relatedLot": "47",
"value": 4
},
{
"id": "191",
"measure": "bids",
"relatedLot": "47",
"value": 4
},
{
"id": "196",
"measure": "bids",
"relatedLot": "24",
"value": 1
},
{
"id": "201",
"measure": "bids",
"relatedLot": "37",
"value": 3
},
{
"id": "206",
"measure": "bids",
"relatedLot": "37",
"value": 3
},
{
"id": "211",
"measure": "bids",
"relatedLot": "8",
"value": 3
},
{
"id": "216",
"measure": "bids",
"relatedLot": "8",
"value": 3
},
{
"id": "221",
"measure": "bids",
"relatedLot": "13",
"value": 2
},
{
"id": "226",
"measure": "bids",
"relatedLot": "18",
"value": 3
},
{
"id": "231",
"measure": "bids",
"relatedLot": "18",
"value": 3
},
{
"id": "236",
"measure": "bids",
"relatedLot": "14",
"value": 3
},
{
"id": "241",
"measure": "bids",
"relatedLot": "26",
"value": 1
},
{
"id": "246",
"measure": "bids",
"relatedLot": "12",
"value": 3
},
{
"id": "251",
"measure": "bids",
"relatedLot": "32",
"value": 4
},
{
"id": "256",
"measure": "bids",
"relatedLot": "32",
"value": 4
},
{
"id": "261",
"measure": "bids",
"relatedLot": "32",
"value": 4
},
{
"id": "266",
"measure": "bids",
"relatedLot": "32",
"value": 4
},
{
"id": "271",
"measure": "bids",
"relatedLot": "10",
"value": 3
},
{
"id": "276",
"measure": "bids",
"relatedLot": "10",
"value": 3
},
{
"id": "281",
"measure": "bids",
"relatedLot": "44",
"value": 4
},
{
"id": "286",
"measure": "bids",
"relatedLot": "44",
"value": 4
},
{
"id": "291",
"measure": "bids",
"relatedLot": "44",
"value": 4
},
{
"id": "296",
"measure": "bids",
"relatedLot": "44",
"value": 4
},
{
"id": "301",
"measure": "bids",
"relatedLot": "34",
"value": 4
},
{
"id": "306",
"measure": "bids",
"relatedLot": "48",
"value": 2
},
{
"id": "311",
"measure": "bids",
"relatedLot": "9",
"value": 3
},
{
"id": "316",
"measure": "bids",
"relatedLot": "28",
"value": 4
},
{
"id": "321",
"measure": "bids",
"relatedLot": "49",
"value": 4
},
{
"id": "326",
"measure": "bids",
"relatedLot": "43",
"value": 4
},
{
"id": "331",
"measure": "bids",
"relatedLot": "43",
"value": 4
},
{
"id": "336",
"measure": "bids",
"relatedLot": "43",
"value": 4
},
{
"id": "341",
"measure": "bids",
"relatedLot": "43",
"value": 4
},
{
"id": "346",
"measure": "bids",
"relatedLot": "46",
"value": 4
},
{
"id": "351",
"measure": "bids",
"relatedLot": "46",
"value": 4
},
{
"id": "356",
"measure": "bids",
"relatedLot": "46",
"value": 4
},
{
"id": "361",
"measure": "bids",
"relatedLot": "46",
"value": 4
},
{
"id": "366",
"measure": "bids",
"relatedLot": "15",
"value": 4
},
{
"id": "371",
"measure": "bids",
"relatedLot": "15",
"value": 4
},
{
"id": "376",
"measure": "bids",
"relatedLot": "42",
"value": 4
},
{
"id": "381",
"measure": "bids",
"relatedLot": "42",
"value": 4
},
{
"id": "386",
"measure": "bids",
"relatedLot": "42",
"value": 4
},
{
"id": "391",
"measure": "bids",
"relatedLot": "42",
"value": 4
},
{
"id": "396",
"measure": "bids",
"relatedLot": "40",
"value": 4
},
{
"id": "401",
"measure": "bids",
"relatedLot": "40",
"value": 4
},
{
"id": "406",
"measure": "bids",
"relatedLot": "40",
"value": 4
},
{
"id": "411",
"measure": "bids",
"relatedLot": "40",
"value": 4
},
{
"id": "416",
"measure": "bids",
"relatedLot": "41",
"value": 4
},
{
"id": "421",
"measure": "bids",
"relatedLot": "41",
"value": 4
},
{
"id": "426",
"measure": "bids",
"relatedLot": "41",
"value": 4
},
{
"id": "431",
"measure": "bids",
"relatedLot": "41",
"value": 4
},
{
"id": "436",
"measure": "bids",
"relatedLot": "35",
"value": 3
},
{
"id": "441",
"measure": "bids",
"relatedLot": "45",
"value": 4
},
{
"id": "446",
"measure": "bids",
"relatedLot": "45",
"value": 4
},
{
"id": "451",
"measure": "bids",
"relatedLot": "45",
"value": 4
},
{
"id": "456",
"measure": "bids",
"relatedLot": "45",
"value": 4
},
{
"id": "461",
"measure": "bids",
"relatedLot": "20",
"value": 3
},
{
"id": "2",
"measure": "smeBids",
"relatedLot": "25",
"value": 0
},
{
"id": "7",
"measure": "smeBids",
"relatedLot": "22",
"value": 1
},
{
"id": "12",
"measure": "smeBids",
"relatedLot": "1",
"value": 1
},
{
"id": "17",
"measure": "smeBids",
"relatedLot": "1",
"value": 1
},
{
"id": "22",
"measure": "smeBids",
"relatedLot": "1",
"value": 1
},
{
"id": "27",
"measure": "smeBids",
"relatedLot": "1",
"value": 1
},
{
"id": "32",
"measure": "smeBids",
"relatedLot": "2",
"value": 1
},
{
"id": "37",
"measure": "smeBids",
"relatedLot": "2",
"value": 1
},
{
"id": "42",
"measure": "smeBids",
"relatedLot": "2",
"value": 1
},
{
"id": "47",
"measure": "smeBids",
"relatedLot": "2",
"value": 1
},
{
"id": "52",
"measure": "smeBids",
"relatedLot": "3",
"value": 1
},
{
"id": "57",
"measure": "smeBids",
"relatedLot": "3",
"value": 1
},
{
"id": "62",
"measure": "smeBids",
"relatedLot": "3",
"value": 1
},
{
"id": "67",
"measure": "smeBids",
"relatedLot": "4",
"value": 1
},
{
"id": "72",
"measure": "smeBids",
"relatedLot": "4",
"value": 1
},
{
"id": "77",
"measure": "smeBids",
"relatedLot": "4",
"value": 1
},
{
"id": "82",
"measure": "smeBids",
"relatedLot": "5",
"value": 1
},
{
"id": "87",
"measure": "smeBids",
"relatedLot": "11",
"value": 1
},
{
"id": "92",
"measure": "smeBids",
"relatedLot": "33",
"value": 1
},
{
"id": "97",
"measure": "smeBids",
"relatedLot": "38",
"value": 1
},
{
"id": "102",
"measure": "smeBids",
"relatedLot": "17",
"value": 1
},
{
"id": "107",
"measure": "smeBids",
"relatedLot": "27",
"value": 1
},
{
"id": "112",
"measure": "smeBids",
"relatedLot": "31",
"value": 1
},
{
"id": "117",
"measure": "smeBids",
"relatedLot": "23",
"value": 1
},
{
"id": "122",
"measure": "smeBids",
"relatedLot": "19",
"value": 1
},
{
"id": "127",
"measure": "smeBids",
"relatedLot": "6",
"value": 1
},
{
"id": "132",
"measure": "smeBids",
"relatedLot": "39",
"value": 1
},
{
"id": "137",
"measure": "smeBids",
"relatedLot": "39",
"value": 1
},
{
"id": "142",
"measure": "smeBids",
"relatedLot": "7",
"value": 1
},
{
"id": "147",
"measure": "smeBids",
"relatedLot": "36",
"value": 1
},
{
"id": "152",
"measure": "smeBids",
"relatedLot": "36",
"value": 1
},
{
"id": "157",
"measure": "smeBids",
"relatedLot": "50",
"value": 1
},
{
"id": "162",
"measure": "smeBids",
"relatedLot": "21",
"value": 1
},
{
"id": "167",
"measure": "smeBids",
"relatedLot": "30",
"value": 1
},
{
"id": "172",
"measure": "smeBids",
"relatedLot": "16",
"value": 1
},
{
"id": "177",
"measure": "smeBids",
"relatedLot": "47",
"value": 1
},
{
"id": "182",
"measure": "smeBids",
"relatedLot": "47",
"value": 1
},
{
"id": "187",
"measure": "smeBids",
"relatedLot": "47",
"value": 1
},
{
"id": "192",
"measure": "smeBids",
"relatedLot": "47",
"value": 1
},
{
"id": "197",
"measure": "smeBids",
"relatedLot": "24",
"value": 0
},
{
"id": "202",
"measure": "smeBids",
"relatedLot": "37",
"value": 1
},
{
"id": "207",
"measure": "smeBids",
"relatedLot": "37",
"value": 1
},
{
"id": "212",
"measure": "smeBids",
"relatedLot": "8",
"value": 1
},
{
"id": "217",
"measure": "smeBids",
"relatedLot": "8",
"value": 1
},
{
"id": "222",
"measure": "smeBids",
"relatedLot": "13",
"value": 0
},
{
"id": "227",
"measure": "smeBids",
"relatedLot": "18",
"value": 1
},
{
"id": "232",
"measure": "smeBids",
"relatedLot": "18",
"value": 1
},
{
"id": "237",
"measure": "smeBids",
"relatedLot": "14",
"value": 1
},
{
"id": "242",
"measure": "smeBids",
"relatedLot": "26",
"value": 0
},
{
"id": "247",
"measure": "smeBids",
"relatedLot": "12",
"value": 1
},
{
"id": "252",
"measure": "smeBids",
"relatedLot": "32",
"value": 1
},
{
"id": "257",
"measure": "smeBids",
"relatedLot": "32",
"value": 1
},
{
"id": "262",
"measure": "smeBids",
"relatedLot": "32",
"value": 1
},
{
"id": "267",
"measure": "smeBids",
"relatedLot": "32",
"value": 1
},
{
"id": "272",
"measure": "smeBids",
"relatedLot": "10",
"value": 1
},
{
"id": "277",
"measure": "smeBids",
"relatedLot": "10",
"value": 1
},
{
"id": "282",
"measure": "smeBids",
"relatedLot": "44",
"value": 1
},
{
"id": "287",
"measure": "smeBids",
"relatedLot": "44",
"value": 1
},
{
"id": "292",
"measure": "smeBids",
"relatedLot": "44",
"value": 1
},
{
"id": "297",
"measure": "smeBids",
"relatedLot": "44",
"value": 1
},
{
"id": "302",
"measure": "smeBids",
"relatedLot": "34",
"value": 1
},
{
"id": "307",
"measure": "smeBids",
"relatedLot": "48",
"value": 1
},
{
"id": "312",
"measure": "smeBids",
"relatedLot": "9",
"value": 1
},
{
"id": "317",
"measure": "smeBids",
"relatedLot": "28",
"value": 1
},
{
"id": "322",
"measure": "smeBids",
"relatedLot": "49",
"value": 1
},
{
"id": "327",
"measure": "smeBids",
"relatedLot": "43",
"value": 1
},
{
"id": "332",
"measure": "smeBids",
"relatedLot": "43",
"value": 1
},
{
"id": "337",
"measure": "smeBids",
"relatedLot": "43",
"value": 1
},
{
"id": "342",
"measure": "smeBids",
"relatedLot": "43",
"value": 1
},
{
"id": "347",
"measure": "smeBids",
"relatedLot": "46",
"value": 1
},
{
"id": "352",
"measure": "smeBids",
"relatedLot": "46",
"value": 1
},
{
"id": "357",
"measure": "smeBids",
"relatedLot": "46",
"value": 1
},
{
"id": "362",
"measure": "smeBids",
"relatedLot": "46",
"value": 1
},
{
"id": "367",
"measure": "smeBids",
"relatedLot": "15",
"value": 1
},
{
"id": "372",
"measure": "smeBids",
"relatedLot": "15",
"value": 1
},
{
"id": "377",
"measure": "smeBids",
"relatedLot": "42",
"value": 1
},
{
"id": "382",
"measure": "smeBids",
"relatedLot": "42",
"value": 1
},
{
"id": "387",
"measure": "smeBids",
"relatedLot": "42",
"value": 1
},
{
"id": "392",
"measure": "smeBids",
"relatedLot": "42",
"value": 1
},
{
"id": "397",
"measure": "smeBids",
"relatedLot": "40",
"value": 1
},
{
"id": "402",
"measure": "smeBids",
"relatedLot": "40",
"value": 1
},
{
"id": "407",
"measure": "smeBids",
"relatedLot": "40",
"value": 1
},
{
"id": "412",
"measure": "smeBids",
"relatedLot": "40",
"value": 1
},
{
"id": "417",
"measure": "smeBids",
"relatedLot": "41",
"value": 1
},
{
"id": "422",
"measure": "smeBids",
"relatedLot": "41",
"value": 1
},
{
"id": "427",
"measure": "smeBids",
"relatedLot": "41",
"value": 1
},
{
"id": "432",
"measure": "smeBids",
"relatedLot": "41",
"value": 1
},
{
"id": "437",
"measure": "smeBids",
"relatedLot": "35",
"value": 0
},
{
"id": "442",
"measure": "smeBids",
"relatedLot": "45",
"value": 1
},
{
"id": "447",
"measure": "smeBids",
"relatedLot": "45",
"value": 1
},
{
"id": "452",
"measure": "smeBids",
"relatedLot": "45",
"value": 1
},
{
"id": "457",
"measure": "smeBids",
"relatedLot": "45",
"value": 1
},
{
"id": "462",
"measure": "smeBids",
"relatedLot": "20",
"value": 1
},
{
"id": "3",
"measure": "foreignBidsFromEU",
"relatedLot": "25",
"value": 1
},
{
"id": "8",
"measure": "foreignBidsFromEU",
"relatedLot": "22",
"value": 3
},
{
"id": "13",
"measure": "foreignBidsFromEU",
"relatedLot": "1",
"value": 4
},
{
"id": "18",
"measure": "foreignBidsFromEU",
"relatedLot": "1",
"value": 4
},
{
"id": "23",
"measure": "foreignBidsFromEU",
"relatedLot": "1",
"value": 4
},
{
"id": "28",
"measure": "foreignBidsFromEU",
"relatedLot": "1",
"value": 4
},
{
"id": "33",
"measure": "foreignBidsFromEU",
"relatedLot": "2",
"value": 4
},
{
"id": "38",
"measure": "foreignBidsFromEU",
"relatedLot": "2",
"value": 4
},
{
"id": "43",
"measure": "foreignBidsFromEU",
"relatedLot": "2",
"value": 4
},
{
"id": "48",
"measure": "foreignBidsFromEU",
"relatedLot": "2",
"value": 4
},
{
"id": "53",
"measure": "foreignBidsFromEU",
"relatedLot": "3",
"value": 3
},
{
"id": "58",
"measure": "foreignBidsFromEU",
"relatedLot": "3",
"value": 3
},
{
"id": "63",
"measure": "foreignBidsFromEU",
"relatedLot": "3",
"value": 3
},
{
"id": "68",
"measure": "foreignBidsFromEU",
"relatedLot": "4",
"value": 3
},
{
"id": "73",
"measure": "foreignBidsFromEU",
"relatedLot": "4",
"value": 3
},
{
"id": "78",
"measure": "foreignBidsFromEU",
"relatedLot": "4",
"value": 3
},
{
"id": "83",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 1
},
{
"id": "88",
"measure": "foreignBidsFromEU",
"relatedLot": "11",
"value": 3
},
{
"id": "93",
"measure": "foreignBidsFromEU",
"relatedLot": "33",
"value": 2
},
{
"id": "98",
"measure": "foreignBidsFromEU",
"relatedLot": "38",
"value": 2
},
{
"id": "103",
"measure": "foreignBidsFromEU",
"relatedLot": "17",
"value": 1
},
{
"id": "108",
"measure": "foreignBidsFromEU",
"relatedLot": "27",
"value": 4
},
{
"id": "113",
"measure": "foreignBidsFromEU",
"relatedLot": "31",
"value": 1
},
{
"id": "118",
"measure": "foreignBidsFromEU",
"relatedLot": "23",
"value": 3
},
{
"id": "123",
"measure": "foreignBidsFromEU",
"relatedLot": "19",
"value": 3
},
{
"id": "128",
"measure": "foreignBidsFromEU",
"relatedLot": "6",
"value": 4
},
{
"id": "133",
"measure": "foreignBidsFromEU",
"relatedLot": "39",
"value": 3
},
{
"id": "138",
"measure": "foreignBidsFromEU",
"relatedLot": "39",
"value": 3
},
{
"id": "143",
"measure": "foreignBidsFromEU",
"relatedLot": "7",
"value": 4
},
{
"id": "148",
"measure": "foreignBidsFromEU",
"relatedLot": "36",
"value": 3
},
{
"id": "153",
"measure": "foreignBidsFromEU",
"relatedLot": "36",
"value": 3
},
{
"id": "158",
"measure": "foreignBidsFromEU",
"relatedLot": "50",
"value": 1
},
{
"id": "163",
"measure": "foreignBidsFromEU",
"relatedLot": "21",
"value": 3
},
{
"id": "168",
"measure": "foreignBidsFromEU",
"relatedLot": "30",
"value": 4
},
{
"id": "173",
"measure": "foreignBidsFromEU",
"relatedLot": "16",
"value": 1
},
{
"id": "178",
"measure": "foreignBidsFromEU",
"relatedLot": "47",
"value": 4
},
{
"id": "183",
"measure": "foreignBidsFromEU",
"relatedLot": "47",
"value": 4
},
{
"id": "188",
"measure": "foreignBidsFromEU",
"relatedLot": "47",
"value": 4
},
{
"id": "193",
"measure": "foreignBidsFromEU",
"relatedLot": "47",
"value": 4
},
{
"id": "198",
"measure": "foreignBidsFromEU",
"relatedLot": "24",
"value": 1
},
{
"id": "203",
"measure": "foreignBidsFromEU",
"relatedLot": "37",
"value": 3
},
{
"id": "208",
"measure": "foreignBidsFromEU",
"relatedLot": "37",
"value": 3
},
{
"id": "213",
"measure": "foreignBidsFromEU",
"relatedLot": "8",
"value": 3
},
{
"id": "218",
"measure": "foreignBidsFromEU",
"relatedLot": "8",
"value": 3
},
{
"id": "223",
"measure": "foreignBidsFromEU",
"relatedLot": "13",
"value": 2
},
{
"id": "228",
"measure": "foreignBidsFromEU",
"relatedLot": "18",
"value": 3
},
{
"id": "233",
"measure": "foreignBidsFromEU",
"relatedLot": "18",
"value": 3
},
{
"id": "238",
"measure": "foreignBidsFromEU",
"relatedLot": "14",
"value": 3
},
{
"id": "243",
"measure": "foreignBidsFromEU",
"relatedLot": "26",
"value": 1
},
{
"id": "248",
"measure": "foreignBidsFromEU",
"relatedLot": "12",
"value": 3
},
{
"id": "253",
"measure": "foreignBidsFromEU",
"relatedLot": "32",
"value": 4
},
{
"id": "258",
"measure": "foreignBidsFromEU",
"relatedLot": "32",
"value": 4
},
{
"id": "263",
"measure": "foreignBidsFromEU",
"relatedLot": "32",
"value": 4
},
{
"id": "268",
"measure": "foreignBidsFromEU",
"relatedLot": "32",
"value": 4
},
{
"id": "273",
"measure": "foreignBidsFromEU",
"relatedLot": "10",
"value": 3
},
{
"id": "278",
"measure": "foreignBidsFromEU",
"relatedLot": "10",
"value": 3
},
{
"id": "283",
"measure": "foreignBidsFromEU",
"relatedLot": "44",
"value": 4
},
{
"id": "288",
"measure": "foreignBidsFromEU",
"relatedLot": "44",
"value": 4
},
{
"id": "293",
"measure": "foreignBidsFromEU",
"relatedLot": "44",
"value": 4
},
{
"id": "298",
"measure": "foreignBidsFromEU",
"relatedLot": "44",
"value": 4
},
{
"id": "303",
"measure": "foreignBidsFromEU",
"relatedLot": "34",
"value": 4
},
{
"id": "308",
"measure": "foreignBidsFromEU",
"relatedLot": "48",
"value": 2
},
{
"id": "313",
"measure": "foreignBidsFromEU",
"relatedLot": "9",
"value": 3
},
{
"id": "318",
"measure": "foreignBidsFromEU",
"relatedLot": "28",
"value": 4
},
{
"id": "323",
"measure": "foreignBidsFromEU",
"relatedLot": "49",
"value": 4
},
{
"id": "328",
"measure": "foreignBidsFromEU",
"relatedLot": "43",
"value": 4
},
{
"id": "333",
"measure": "foreignBidsFromEU",
"relatedLot": "43",
"value": 4
},
{
"id": "338",
"measure": "foreignBidsFromEU",
"relatedLot": "43",
"value": 4
},
{
"id": "343",
"measure": "foreignBidsFromEU",
"relatedLot": "43",
"value": 4
},
{
"id": "348",
"measure": "foreignBidsFromEU",
"relatedLot": "46",
"value": 4
},
{
"id": "353",
"measure": "foreignBidsFromEU",
"relatedLot": "46",
"value": 4
},
{
"id": "358",
"measure": "foreignBidsFromEU",
"relatedLot": "46",
"value": 4
},
{
"id": "363",
"measure": "foreignBidsFromEU",
"relatedLot": "46",
"value": 4
},
{
"id": "368",
"measure": "foreignBidsFromEU",
"relatedLot": "15",
"value": 4
},
{
"id": "373",
"measure": "foreignBidsFromEU",
"relatedLot": "15",
"value": 4
},
{
"id": "378",
"measure": "foreignBidsFromEU",
"relatedLot": "42",
"value": 4
},
{
"id": "383",
"measure": "foreignBidsFromEU",
"relatedLot": "42",
"value": 4
},
{
"id": "388",
"measure": "foreignBidsFromEU",
"relatedLot": "42",
"value": 4
},
{
"id": "393",
"measure": "foreignBidsFromEU",
"relatedLot": "42",
"value": 4
},
{
"id": "398",
"measure": "foreignBidsFromEU",
"relatedLot": "40",
"value": 4
},
{
"id": "403",
"measure": "foreignBidsFromEU",
"relatedLot": "40",
"value": 4
},
{
"id": "408",
"measure": "foreignBidsFromEU",
"relatedLot": "40",
"value": 4
},
{
"id": "413",
"measure": "foreignBidsFromEU",
"relatedLot": "40",
"value": 4
},
{
"id": "418",
"measure": "foreignBidsFromEU",
"relatedLot": "41",
"value": 4
},
{
"id": "423",
"measure": "foreignBidsFromEU",
"relatedLot": "41",
"value": 4
},
{
"id": "428",
"measure": "foreignBidsFromEU",
"relatedLot": "41",
"value": 4
},
{
"id": "433",
"measure": "foreignBidsFromEU",
"relatedLot": "41",
"value": 4
},
{
"id": "438",
"measure": "foreignBidsFromEU",
"relatedLot": "35",
"value": 3
},
{
"id": "443",
"measure": "foreignBidsFromEU",
"relatedLot": "45",
"value": 4
},
{
"id": "448",
"measure": "foreignBidsFromEU",
"relatedLot": "45",
"value": 4
},
{
"id": "453",
"measure": "foreignBidsFromEU",
"relatedLot": "45",
"value": 4
},
{
"id": "458",
"measure": "foreignBidsFromEU",
"relatedLot": "45",
"value": 4
},
{
"id": "463",
"measure": "foreignBidsFromEU",
"relatedLot": "20",
"value": 3
},
{
"id": "4",
"measure": "foreignBidsFromNonEU",
"relatedLot": "25",
"value": 0
},
{
"id": "9",
"measure": "foreignBidsFromNonEU",
"relatedLot": "22",
"value": 0
},
{
"id": "14",
"measure": "foreignBidsFromNonEU",
"relatedLot": "1",
"value": 0
},
{
"id": "19",
"measure": "foreignBidsFromNonEU",
"relatedLot": "1",
"value": 0
},
{
"id": "24",
"measure": "foreignBidsFromNonEU",
"relatedLot": "1",
"value": 0
},
{
"id": "29",
"measure": "foreignBidsFromNonEU",
"relatedLot": "1",
"value": 0
},
{
"id": "34",
"measure": "foreignBidsFromNonEU",
"relatedLot": "2",
"value": 0
},
{
"id": "39",
"measure": "foreignBidsFromNonEU",
"relatedLot": "2",
"value": 0
},
{
"id": "44",
"measure": "foreignBidsFromNonEU",
"relatedLot": "2",
"value": 0
},
{
"id": "49",
"measure": "foreignBidsFromNonEU",
"relatedLot": "2",
"value": 0
},
{
"id": "54",
"measure": "foreignBidsFromNonEU",
"relatedLot": "3",
"value": 0
},
{
"id": "59",
"measure": "foreignBidsFromNonEU",
"relatedLot": "3",
"value": 0
},
{
"id": "64",
"measure": "foreignBidsFromNonEU",
"relatedLot": "3",
"value": 0
},
{
"id": "69",
"measure": "foreignBidsFromNonEU",
"relatedLot": "4",
"value": 0
},
{
"id": "74",
"measure": "foreignBidsFromNonEU",
"relatedLot": "4",
"value": 0
},
{
"id": "79",
"measure": "foreignBidsFromNonEU",
"relatedLot": "4",
"value": 0
},
{
"id": "84",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 0
},
{
"id": "89",
"measure": "foreignBidsFromNonEU",
"relatedLot": "11",
"value": 0
},
{
"id": "94",
"measure": "foreignBidsFromNonEU",
"relatedLot": "33",
"value": 0
},
{
"id": "99",
"measure": "foreignBidsFromNonEU",
"relatedLot": "38",
"value": 0
},
{
"id": "104",
"measure": "foreignBidsFromNonEU",
"relatedLot": "17",
"value": 0
},
{
"id": "109",
"measure": "foreignBidsFromNonEU",
"relatedLot": "27",
"value": 0
},
{
"id": "114",
"measure": "foreignBidsFromNonEU",
"relatedLot": "31",
"value": 0
},
{
"id": "119",
"measure": "foreignBidsFromNonEU",
"relatedLot": "23",
"value": 0
},
{
"id": "124",
"measure": "foreignBidsFromNonEU",
"relatedLot": "19",
"value": 0
},
{
"id": "129",
"measure": "foreignBidsFromNonEU",
"relatedLot": "6",
"value": 0
},
{
"id": "134",
"measure": "foreignBidsFromNonEU",
"relatedLot": "39",
"value": 0
},
{
"id": "139",
"measure": "foreignBidsFromNonEU",
"relatedLot": "39",
"value": 0
},
{
"id": "144",
"measure": "foreignBidsFromNonEU",
"relatedLot": "7",
"value": 0
},
{
"id": "149",
"measure": "foreignBidsFromNonEU",
"relatedLot": "36",
"value": 0
},
{
"id": "154",
"measure": "foreignBidsFromNonEU",
"relatedLot": "36",
"value": 0
},
{
"id": "159",
"measure": "foreignBidsFromNonEU",
"relatedLot": "50",
"value": 0
},
{
"id": "164",
"measure": "foreignBidsFromNonEU",
"relatedLot": "21",
"value": 0
},
{
"id": "169",
"measure": "foreignBidsFromNonEU",
"relatedLot": "30",
"value": 0
},
{
"id": "174",
"measure": "foreignBidsFromNonEU",
"relatedLot": "16",
"value": 0
},
{
"id": "179",
"measure": "foreignBidsFromNonEU",
"relatedLot": "47",
"value": 0
},
{
"id": "184",
"measure": "foreignBidsFromNonEU",
"relatedLot": "47",
"value": 0
},
{
"id": "189",
"measure": "foreignBidsFromNonEU",
"relatedLot": "47",
"value": 0
},
{
"id": "194",
"measure": "foreignBidsFromNonEU",
"relatedLot": "47",
"value": 0
},
{
"id": "199",
"measure": "foreignBidsFromNonEU",
"relatedLot": "24",
"value": 0
},
{
"id": "204",
"measure": "foreignBidsFromNonEU",
"relatedLot": "37",
"value": 0
},
{
"id": "209",
"measure": "foreignBidsFromNonEU",
"relatedLot": "37",
"value": 0
},
{
"id": "214",
"measure": "foreignBidsFromNonEU",
"relatedLot": "8",
"value": 0
},
{
"id": "219",
"measure": "foreignBidsFromNonEU",
"relatedLot": "8",
"value": 0
},
{
"id": "224",
"measure": "foreignBidsFromNonEU",
"relatedLot": "13",
"value": 0
},
{
"id": "229",
"measure": "foreignBidsFromNonEU",
"relatedLot": "18",
"value": 0
},
{
"id": "234",
"measure": "foreignBidsFromNonEU",
"relatedLot": "18",
"value": 0
},
{
"id": "239",
"measure": "foreignBidsFromNonEU",
"relatedLot": "14",
"value": 0
},
{
"id": "244",
"measure": "foreignBidsFromNonEU",
"relatedLot": "26",
"value": 0
},
{
"id": "249",
"measure": "foreignBidsFromNonEU",
"relatedLot": "12",
"value": 0
},
{
"id": "254",
"measure": "foreignBidsFromNonEU",
"relatedLot": "32",
"value": 0
},
{
"id": "259",
"measure": "foreignBidsFromNonEU",
"relatedLot": "32",
"value": 0
},
{
"id": "264",
"measure": "foreignBidsFromNonEU",
"relatedLot": "32",
"value": 0
},
{
"id": "269",
"measure": "foreignBidsFromNonEU",
"relatedLot": "32",
"value": 0
},
{
"id": "274",
"measure": "foreignBidsFromNonEU",
"relatedLot": "10",
"value": 0
},
{
"id": "279",
"measure": "foreignBidsFromNonEU",
"relatedLot": "10",
"value": 0
},
{
"id": "284",
"measure": "foreignBidsFromNonEU",
"relatedLot": "44",
"value": 0
},
{
"id": "289",
"measure": "foreignBidsFromNonEU",
"relatedLot": "44",
"value": 0
},
{
"id": "294",
"measure": "foreignBidsFromNonEU",
"relatedLot": "44",
"value": 0
},
{
"id": "299",
"measure": "foreignBidsFromNonEU",
"relatedLot": "44",
"value": 0
},
{
"id": "304",
"measure": "foreignBidsFromNonEU",
"relatedLot": "34",
"value": 0
},
{
"id": "309",
"measure": "foreignBidsFromNonEU",
"relatedLot": "48",
"value": 0
},
{
"id": "314",
"measure": "foreignBidsFromNonEU",
"relatedLot": "9",
"value": 0
},
{
"id": "319",
"measure": "foreignBidsFromNonEU",
"relatedLot": "28",
"value": 0
},
{
"id": "324",
"measure": "foreignBidsFromNonEU",
"relatedLot": "49",
"value": 0
},
{
"id": "329",
"measure": "foreignBidsFromNonEU",
"relatedLot": "43",
"value": 0
},
{
"id": "334",
"measure": "foreignBidsFromNonEU",
"relatedLot": "43",
"value": 0
},
{
"id": "339",
"measure": "foreignBidsFromNonEU",
"relatedLot": "43",
"value": 0
},
{
"id": "344",
"measure": "foreignBidsFromNonEU",
"relatedLot": "43",
"value": 0
},
{
"id": "349",
"measure": "foreignBidsFromNonEU",
"relatedLot": "46",
"value": 0
},
{
"id": "354",
"measure": "foreignBidsFromNonEU",
"relatedLot": "46",
"value": 0
},
{
"id": "359",
"measure": "foreignBidsFromNonEU",
"relatedLot": "46",
"value": 0
},
{
"id": "364",
"measure": "foreignBidsFromNonEU",
"relatedLot": "46",
"value": 0
},
{
"id": "369",
"measure": "foreignBidsFromNonEU",
"relatedLot": "15",
"value": 0
},
{
"id": "374",
"measure": "foreignBidsFromNonEU",
"relatedLot": "15",
"value": 0
},
{
"id": "379",
"measure": "foreignBidsFromNonEU",
"relatedLot": "42",
"value": 0
},
{
"id": "384",
"measure": "foreignBidsFromNonEU",
"relatedLot": "42",
"value": 0
},
{
"id": "389",
"measure": "foreignBidsFromNonEU",
"relatedLot": "42",
"value": 0
},
{
"id": "394",
"measure": "foreignBidsFromNonEU",
"relatedLot": "42",
"value": 0
},
{
"id": "399",
"measure": "foreignBidsFromNonEU",
"relatedLot": "40",
"value": 0
},
{
"id": "404",
"measure": "foreignBidsFromNonEU",
"relatedLot": "40",
"value": 0
},
{
"id": "409",
"measure": "foreignBidsFromNonEU",
"relatedLot": "40",
"value": 0
},
{
"id": "414",
"measure": "foreignBidsFromNonEU",
"relatedLot": "40",
"value": 0
},
{
"id": "419",
"measure": "foreignBidsFromNonEU",
"relatedLot": "41",
"value": 0
},
{
"id": "424",
"measure": "foreignBidsFromNonEU",
"relatedLot": "41",
"value": 0
},
{
"id": "429",
"measure": "foreignBidsFromNonEU",
"relatedLot": "41",
"value": 0
},
{
"id": "434",
"measure": "foreignBidsFromNonEU",
"relatedLot": "41",
"value": 0
},
{
"id": "439",
"measure": "foreignBidsFromNonEU",
"relatedLot": "35",
"value": 0
},
{
"id": "444",
"measure": "foreignBidsFromNonEU",
"relatedLot": "45",
"value": 0
},
{
"id": "449",
"measure": "foreignBidsFromNonEU",
"relatedLot": "45",
"value": 0
},
{
"id": "454",
"measure": "foreignBidsFromNonEU",
"relatedLot": "45",
"value": 0
},
{
"id": "459",
"measure": "foreignBidsFromNonEU",
"relatedLot": "45",
"value": 0
},
{
"id": "464",
"measure": "foreignBidsFromNonEU",
"relatedLot": "20",
"value": 0
},
{
"id": "5",
"measure": "electronicBids",
"relatedLot": "25",
"value": 1
},
{
"id": "10",
"measure": "electronicBids",
"relatedLot": "22",
"value": 3
},
{
"id": "15",
"measure": "electronicBids",
"relatedLot": "1",
"value": 4
},
{
"id": "20",
"measure": "electronicBids",
"relatedLot": "1",
"value": 4
},
{
"id": "25",
"measure": "electronicBids",
"relatedLot": "1",
"value": 4
},
{
"id": "30",
"measure": "electronicBids",
"relatedLot": "1",
"value": 4
},
{
"id": "35",
"measure": "electronicBids",
"relatedLot": "2",
"value": 4
},
{
"id": "40",
"measure": "electronicBids",
"relatedLot": "2",
"value": 4
},
{
"id": "45",
"measure": "electronicBids",
"relatedLot": "2",
"value": 4
},
{
"id": "50",
"measure": "electronicBids",
"relatedLot": "2",
"value": 4
},
{
"id": "55",
"measure": "electronicBids",
"relatedLot": "3",
"value": 3
},
{
"id": "60",
"measure": "electronicBids",
"relatedLot": "3",
"value": 3
},
{
"id": "65",
"measure": "electronicBids",
"relatedLot": "3",
"value": 3
},
{
"id": "70",
"measure": "electronicBids",
"relatedLot": "4",
"value": 3
},
{
"id": "75",
"measure": "electronicBids",
"relatedLot": "4",
"value": 3
},
{
"id": "80",
"measure": "electronicBids",
"relatedLot": "4",
"value": 3
},
{
"id": "85",
"measure": "electronicBids",
"relatedLot": "5",
"value": 1
},
{
"id": "90",
"measure": "electronicBids",
"relatedLot": "11",
"value": 3
},
{
"id": "95",
"measure": "electronicBids",
"relatedLot": "33",
"value": 2
},
{
"id": "100",
"measure": "electronicBids",
"relatedLot": "38",
"value": 2
},
{
"id": "105",
"measure": "electronicBids",
"relatedLot": "17",
"value": 1
},
{
"id": "110",
"measure": "electronicBids",
"relatedLot": "27",
"value": 4
},
{
"id": "115",
"measure": "electronicBids",
"relatedLot": "31",
"value": 1
},
{
"id": "120",
"measure": "electronicBids",
"relatedLot": "23",
"value": 3
},
{
"id": "125",
"measure": "electronicBids",
"relatedLot": "19",
"value": 3
},
{
"id": "130",
"measure": "electronicBids",
"relatedLot": "6",
"value": 4
},
{
"id": "135",
"measure": "electronicBids",
"relatedLot": "39",
"value": 3
},
{
"id": "140",
"measure": "electronicBids",
"relatedLot": "39",
"value": 3
},
{
"id": "145",
"measure": "electronicBids",
"relatedLot": "7",
"value": 4
},
{
"id": "150",
"measure": "electronicBids",
"relatedLot": "36",
"value": 3
},
{
"id": "155",
"measure": "electronicBids",
"relatedLot": "36",
"value": 3
},
{
"id": "160",
"measure": "electronicBids",
"relatedLot": "50",
"value": 1
},
{
"id": "165",
"measure": "electronicBids",
"relatedLot": "21",
"value": 3
},
{
"id": "170",
"measure": "electronicBids",
"relatedLot": "30",
"value": 4
},
{
"id": "175",
"measure": "electronicBids",
"relatedLot": "16",
"value": 1
},
{
"id": "180",
"measure": "electronicBids",
"relatedLot": "47",
"value": 4
},
{
"id": "185",
"measure": "electronicBids",
"relatedLot": "47",
"value": 4
},
{
"id": "190",
"measure": "electronicBids",
"relatedLot": "47",
"value": 4
},
{
"id": "195",
"measure": "electronicBids",
"relatedLot": "47",
"value": 4
},
{
"id": "200",
"measure": "electronicBids",
"relatedLot": "24",
"value": 1
},
{
"id": "205",
"measure": "electronicBids",
"relatedLot": "37",
"value": 3
},
{
"id": "210",
"measure": "electronicBids",
"relatedLot": "37",
"value": 3
},
{
"id": "215",
"measure": "electronicBids",
"relatedLot": "8",
"value": 3
},
{
"id": "220",
"measure": "electronicBids",
"relatedLot": "8",
"value": 3
},
{
"id": "225",
"measure": "electronicBids",
"relatedLot": "13",
"value": 2
},
{
"id": "230",
"measure": "electronicBids",
"relatedLot": "18",
"value": 3
},
{
"id": "235",
"measure": "electronicBids",
"relatedLot": "18",
"value": 3
},
{
"id": "240",
"measure": "electronicBids",
"relatedLot": "14",
"value": 3
},
{
"id": "245",
"measure": "electronicBids",
"relatedLot": "26",
"value": 1
},
{
"id": "250",
"measure": "electronicBids",
"relatedLot": "12",
"value": 3
},
{
"id": "255",
"measure": "electronicBids",
"relatedLot": "32",
"value": 4
},
{
"id": "260",
"measure": "electronicBids",
"relatedLot": "32",
"value": 4
},
{
"id": "265",
"measure": "electronicBids",
"relatedLot": "32",
"value": 4
},
{
"id": "270",
"measure": "electronicBids",
"relatedLot": "32",
"value": 4
},
{
"id": "275",
"measure": "electronicBids",
"relatedLot": "10",
"value": 3
},
{
"id": "280",
"measure": "electronicBids",
"relatedLot": "10",
"value": 3
},
{
"id": "285",
"measure": "electronicBids",
"relatedLot": "44",
"value": 4
},
{
"id": "290",
"measure": "electronicBids",
"relatedLot": "44",
"value": 4
},
{
"id": "295",
"measure": "electronicBids",
"relatedLot": "44",
"value": 4
},
{
"id": "300",
"measure": "electronicBids",
"relatedLot": "44",
"value": 4
},
{
"id": "305",
"measure": "electronicBids",
"relatedLot": "34",
"value": 4
},
{
"id": "310",
"measure": "electronicBids",
"relatedLot": "48",
"value": 2
},
{
"id": "315",
"measure": "electronicBids",
"relatedLot": "9",
"value": 3
},
{
"id": "320",
"measure": "electronicBids",
"relatedLot": "28",
"value": 4
},
{
"id": "325",
"measure": "electronicBids",
"relatedLot": "49",
"value": 4
},
{
"id": "330",
"measure": "electronicBids",
"relatedLot": "43",
"value": 4
},
{
"id": "335",
"measure": "electronicBids",
"relatedLot": "43",
"value": 4
},
{
"id": "340",
"measure": "electronicBids",
"relatedLot": "43",
"value": 4
},
{
"id": "345",
"measure": "electronicBids",
"relatedLot": "43",
"value": 4
},
{
"id": "350",
"measure": "electronicBids",
"relatedLot": "46",
"value": 4
},
{
"id": "355",
"measure": "electronicBids",
"relatedLot": "46",
"value": 4
},
{
"id": "360",
"measure": "electronicBids",
"relatedLot": "46",
"value": 4
},
{
"id": "365",
"measure": "electronicBids",
"relatedLot": "46",
"value": 4
},
{
"id": "370",
"measure": "electronicBids",
"relatedLot": "15",
"value": 4
},
{
"id": "375",
"measure": "electronicBids",
"relatedLot": "15",
"value": 4
},
{
"id": "380",
"measure": "electronicBids",
"relatedLot": "42",
"value": 4
},
{
"id": "385",
"measure": "electronicBids",
"relatedLot": "42",
"value": 4
},
{
"id": "390",
"measure": "electronicBids",
"relatedLot": "42",
"value": 4
},
{
"id": "395",
"measure": "electronicBids",
"relatedLot": "42",
"value": 4
},
{
"id": "400",
"measure": "electronicBids",
"relatedLot": "40",
"value": 4
},
{
"id": "405",
"measure": "electronicBids",
"relatedLot": "40",
"value": 4
},
{
"id": "410",
"measure": "electronicBids",
"relatedLot": "40",
"value": 4
},
{
"id": "415",
"measure": "electronicBids",
"relatedLot": "40",
"value": 4
},
{
"id": "420",
"measure": "electronicBids",
"relatedLot": "41",
"value": 4
},
{
"id": "425",
"measure": "electronicBids",
"relatedLot": "41",
"value": 4
},
{
"id": "430",
"measure": "electronicBids",
"relatedLot": "41",
"value": 4
},
{
"id": "435",
"measure": "electronicBids",
"relatedLot": "41",
"value": 4
},
{
"id": "440",
"measure": "electronicBids",
"relatedLot": "35",
"value": 3
},
{
"id": "445",
"measure": "electronicBids",
"relatedLot": "45",
"value": 4
},
{
"id": "450",
"measure": "electronicBids",
"relatedLot": "45",
"value": 4
},
{
"id": "455",
"measure": "electronicBids",
"relatedLot": "45",
"value": 4
},
{
"id": "460",
"measure": "electronicBids",
"relatedLot": "45",
"value": 4
},
{
"id": "465",
"measure": "electronicBids",
"relatedLot": "20",
"value": 3
}
]
},
"links": [
{
"rel": "prev",
"href": "https://ted.europa.eu/udl?uri=TED:NOTICE:506278-2020:TEXT:EN:HTML"
}
],
"language": "en"
}